FAM160A1-DT

Across TCGA pan-cancer cohorts, FAM160A1-DT RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of FAM160A1-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FAM160A1-DT RNA is repressed in tumor relative to normal tissue. In most cancer types FAM160A1-DT is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and STAD are the cancer types where FAM160A1-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM160A1-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.655	<.001	10	view →
KICH	Female	II,III,IV	−1.601	<.001	8	view →
STAD	All	All	+0.734	<.001	6	view →
HNSC	All	All	+0.489	<.001	6	view →
BRCA	All	II,III,IV	+0.474	<.001	6	view →
COAD	Female	II,III,IV	−0.991	<.001	5	view →
LUSC	All	All	+0.555	<.001	5	view →
KIRP	Male	All	−0.657	<.001	3	view →
BLCA	All	All	+0.591	.043	3	view →
THCA	All	All	−0.420	.017	2	view →
PRAD	All	All	+0.370	.003	2	view →
CHOL	All	All	+0.715	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

FAM160A1-DT–KIRC

Open the KIRC breakdown →